The Trump Administration has officially moved to end two decades of fear-driven misinformation about hormone replacement therapy (HRT).
Health and Human Services Secretary Robert F. Kennedy Jr. announced that the FDA will remove misleading “black box” warnings placed on HRT medications in 2003, warnings that discouraged millions of women from receiving life-improving treatment during menopause.
Flanked by FDA Commissioner Dr. Marty Makary, Second Lady Usha Vance, and Labor Secretary Lori Chavez-DeRemer, Kennedy said the administration’s decision “restores integrity to medicine and faith in public health.”
For years, women were warned—based on a flawed and fear-mongering 2002 study—that HRT could increase the risk of breast cancer and heart disease. Yet the Women’s Health Initiative (WHI) data, now reanalyzed, showed those risks were statistically insignificant and misapplied to women far older than the typical menopause patient.
The FDA’s action follows a comprehensive scientific review, an expert panel in July, and months of public comment.
The announcement also included the approval of two new drugs, a long-awaited generic version of Premarin, which will make HRT more affordable, and a non-hormonal treatment for women who cannot or choose not to use hormone therapy.
RFK Jr.:
“For more than two decades, the American medical establishment turned its back on women. Millions of women were told to fear the very therapy that could have given them strength, peace, and dignity through one of life’s most difficult transitions—menopause. That ends today.The FDA is initiating the removal of broad black box warnings from hormone replacement therapy products for menopause.
We’re challenging outdated thinking and recommitting to evidence-based medicine that empowers rather than restricts. When prescribed responsibly—and started early—hormone replacement therapy transforms the lives of women.
It has been found to reduce the risk of cardiovascular disease and mortality by as much as 50%, Alzheimer’s disease by 35%, bone fractures by 50–60%, as well as reducing cognitive decline and all-cause mortality. In other words, extending lives by as much as ten years.
It helps women sleep better, think more clearly, and live fuller, longer, and healthier lives. In short, it restores balance—not just hormonally, but emotionally and physically.
That’s why, in 1989, approximately 27% of postmenopausal women took hormone replacement therapy. But then, in 2002, a study called the Women’s Health Initiative found that women taking hormone replacement therapy may have an increased risk of breast cancer diagnosis—not mortality, but diagnosis.
The study was not statistically significant, but it triggered a media frenzy that led to the FDA applying unscientific black box warnings to all hormone replacement therapy products in 2003.
The label was designed to frighten women and to silence doctors. It warned of diseases and dangers that the data simply did not support.
Bureaucrats at the FDA reacted out of fear, not gold-standard science. Instead of correcting the record, the medical establishment doubled down in groupthink. The consequences have been devastating.
Since that decision, more than 50 million American women have been scared away from treatments that could have eased their suffering and extended their lives.
Before the panic, one in four women used hormone replacement therapy. Today, it’s fewer than one in twenty. That’s not progress—that’s neglect. That’s malpractice. We can no longer accept a culture of fear that blocks innovation and keeps patients from proven therapies.
But today, thanks to President Trump’s bold leadership and unwavering commitment to restoring trust in public health—and the courage of Commissioner Marty McCarry—the FDA is correcting that mistake.
After a thorough, evidence-based review of decades of scientific data, expert panel analysis, and public testimony, the FDA is announcing today that it will remove the misleading black box warnings from all HRT products.
For the first time in a generation, the FDA is standing with science and standing with women. The era of ignoring women’s health is over. The era of patronizing women is over.
The FDA will follow the science, and America’s women will finally get the care, the respect, and the honesty they deserve.
Today, we are restoring integrity to medicine, restoring faith in public health, and restoring balance to the lives of millions of women who have been ignored for too long. And that’s what it means to make America healthy again.”
WATCH:
RFK Jr. has announced that the FDA will remove the black box warnings from hormone replacement therapy for women — ending decades of medical neglect.
“For more than two decades, the American medical establishment turned its back on women.”
“We’re challenging outdated thinking… pic.twitter.com/J60lbWxR4j
— MAHA Action (@MAHA_Action) November 10, 2025
The Real Benefits of HRT According to HHS’ Fact Sheet
Menopausal hormone therapies, also commonly referred to as hormone replacement therapy or (HRT), are approved to provide relief from common menopause symptoms, such as hot flashes and night sweats. Women may be under-utilizing approved therapies that can alleviate menopause symptoms and improve women’s health because of U.S. Food and Drug Administration (FDA) “black box” warnings about the risks associated with these drugs that the agency is removing.
About HRT
- HRT is FDA-approved for relief from common menopausal symptoms, such as hot flashes and night sweats (also known as vasomotor symptoms) and symptoms due to changes to the vagina, vulva, and urinary tract caused by decreased estrogen, also known as vulvovaginal atrophy or genitourinary syndrome of menopause. Some HRT products are also approved for the prevention of osteoporosis (bone weakening).
- Studies have provided evidence that starting HRT within ten years of the onset of menopause can have numerous benefits which for most women outweigh potential risks. Benefits include a reduced risk of all-cause mortality and fractures. HRT has also been associated with 50% reduction in heart attack risk, 64% reduction in cognitive decline, and 35% lower risk of Alzheimer’s.
- An analysis of 30 trials with 26,708 women participants found HRT was not associated with increased cancer mortality. In fact, women who start HRT before age 60 appear to have a decreased mortality risk.
Removal of “Black Box” Warnings
- The FDA is requesting that companies make changes to the labeling to provide current, accurate and balanced information about the benefits and risks of these drugs, so women, in consultation with their healthcare providers, can make the best decisions for their health.
- Specifically, the agency is working with companies to update language in product labeling to remove references to risks of cardiovascular disease, breast cancer, and probable dementia. The FDA is not seeking to remove the boxed warning for endometrial cancer for systemic estrogen-alone products.
- Though the starting time of HRT and duration of use are decisions made between the prescriber and the individual patient, the FDA’s labeled recommendation will be to start HRT within 10 years of menopause onset or before 60 years of age for systemic HRT.
- This action follows the FDA’s assessment of the current relevant literature, including a reanalysis of data from younger cohorts of patients who initiated HRT within ten years of the onset of menopause.
- The FDA recently approved a generic version of Premarin (conjugated estrogens) tablets, a complex mixture of estrogens used to treat various conditions related to menopause and hormone deficiencies.
- The FDA has also approved non-hormonal medication for treating moderate to severe vasomotor symptoms, such as hot flashes.
The post Trump Administration Ends 20 Years of ‘Misinformation’ — HHS Lifts Misleading Black Box Warnings on Hormone Replacement Therapy to Help Women Through Menopause appeared first on The Gateway Pundit.